Novartis licenses vaccine candidates from U.S. group
ZURICH (Reuters) - Novartis AG will license a program of vaccines from U.S. group AlphaVax against cytomegalovirus (CMV) infections, which can cause disability in newborn babies, the Swiss drugmaker said on Monday.
The deal includes vaccines to prevent Helicobacter pylori infections, a major cause of gastritis that can lead to gastric cancer, and another potential immunization against neonatal sepsis and meningitis.
Novartis will pay AlphaVax $20 million upfront for the investigational CMV program and also has rights of first negotiation on a preclinical respiratory syncytial virus (RSV) program.
There are no approved vaccines to prevent CMV infections and the lead vaccine candidate in the deal is expected to enter mid-stage clinical trials in 2009.
The Swiss company also has an option to make an equity investment at the end of mid-stage trials for 4 million shares. AlphaVax will be eligible for milestones and royalties.
CMV infects about 86,000 newborns in the U.S. and European Union each year, causing 700 deaths and 17,500 cases of severe disability, Novartis said.
(Reporting by Sam Cage)
- Six people injured when camera catches fire at 30 Rockefeller Plaza
- Israel holds off on escalating Gaza barrage; West wants truce |
- Russia warns Ukraine after shell crosses border |
- Exclusive: YouTube weighs funding efforts to boost premium content - sources
- 'Excessive' rubbing of engine blades caused F-35 failure: Pentagon
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video